UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The Lancet (British edition), ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 219 - 229
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Carotid Artery Diseases - complications | Male | Peripheral Arterial Disease - complications | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Lower Extremity - surgery | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Rivaroxaban - therapeutic use | Carotid Artery Diseases - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Peripheral Arterial Disease - drug therapy | Carotid Artery Diseases - epidemiology | Morbidity | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Peripheral Arterial Disease - epidemiology | Factor Xa Inhibitors - adverse effects | Aged | Myocardial Infarction - prevention & control | Amputation - statistics & numerical data | Hemorrhage - chemically induced | Lower Extremity - blood supply | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Heart attacks | Medical imaging | Mortality | Clinical trials | Cardiovascular disease | Patients | Disease control | Evidence-based medicine | Carotid arteries | Disease prevention | Coronary vessels | Blood pressure | Carotid artery | Acute coronary syndromes | Thromboembolism | Health risk assessment | Index Medicus | Abridged Index Medicus | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Amputation | Drug | drug therapy | chemically induced | complications | prevention & control | Peripheral Arterial Disease | etiology | Clinical Medicine | Myocardial Infarction | statistics & numerical data | blood supply | Carotid Artery Diseases | Platelet Aggregation Inhibitors | adverse effects | mortality | Lower Extremity | Dose-Response Relationship | therapeutic use | surgery
Journal Article
The Lancet (British edition), ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 205 - 218
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Male | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Coronary Artery Disease - drug therapy | Morbidity | Factor Xa Inhibitors - therapeutic use | Factor Xa Inhibitors - adverse effects | Aged | Coronary Artery Disease - epidemiology | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Anticoagulants | Aspirin | Stroke | Heart attacks | Mortality | Coronary artery | Clinical trials | Cardiovascular disease | Coronary artery disease | Disease control | Evidence-based medicine | Disease prevention | Coronary vessels | Acute coronary syndromes | Thromboembolism | Health risk assessment | Drug therapy | Heart diseases | Index Medicus | Abridged Index Medicus | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Drug | drug therapy | chemically induced | prevention & control | Coronary Artery Disease | Clinical Medicine | Myocardial Infarction | Platelet Aggregation Inhibitors | adverse effects | mortality | Dose-Response Relationship | therapeutic use
Journal Article
No results were found for your search.
Cannot display more than 1000 results, please narrow the terms of your search.